Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivativesReport as inadecuate




Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives - Download this document for free, or read online. Document in PDF available to download.

Purpose

To evaluate the corneal epitheliotropic abilities of two commercialized human platelet lysates HPLs and to compare the results with other blood derivatives, including human peripheral serum HPS and bovine fetal serum FBS.

Methods

In vitro, human corneal epithelial cells were incubated in various concentrations 0%, 3%, 5% and 10% of blood derivatives. Two commercialized HPLs, including UltraGRO TM Helios, Atlanta, GA and PLTMax Mill Creek, Rochester, MI, were tested and compared with HPS and FBS. Scratch-induced directional wounding assay was performed to evaluate cellular migration. MTS assay was used to evaluate cellular proliferation. Cellular differentiation was examined by scanning electron microscopy, inverted microscopy and transepithelial electrical resistance. Sprague-Dawley rats were used to evaluate the effects of the blood derivatives on corneal epithelial wound healing in vivo. Different blood derivatives were applied topically every 2 hours for 2 days after corneal epithelial debridement. The concentrations of epidermal growth factor EGF, transforming growth factor -β1 TGF-β1, fibronectin, platelet-derived growth factor-AB PDGF-AB, PDGF-BB, and hyaluronic acid in different blood derivatives were evaluated by enzyme-linked immunosorbent assay ELISA.

Results

In vitro experiments demonstrated statistically comparable epitheliotropic characteristics in cellular proliferation, migration, and differentiation for the two commercialized HPLs compared to FBS and HPS. Cells cultured without any serum were used as control group. The epitheliotropic capacities were statistically higher in the two commercialized HPLs compared to the control group p<0.05. Among the different concentrations of blood derivatives, the preparations with 3% yielded better outcomes compared to 5% and 10%. In rats, HPLs also caused improved but not statistically significant wound healing compared to HPS. All the blood derivatives had better wound healing ratios than the control group p<0.05. In the quantification of epitheliotropic factors, UltraGRO and PLTMax had significantly higher levels of EGF, TGF- β1, fibronectin than human peripheral serum p<0.05.

Conclusions

Both commercialized HPLs showed comparable corneal epitheliotropic abilities and wound healing rates compared to HPS and FBS in the in vivo and in vitro studies. Our results suggest that HPLs may have the potential to replace HPS in the treatment of corneal epithelial problems.



Author: Chien-Jung Huang, Yi-Chen Sun, Karen Christopher, Amy Shih-I Pai, Chia-Ju Lu, Fung-Rong Hu, Szu-Yuan Lin , Wei-Li Chen

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents